skip to contentskip to secondary navigation
Getting to the centre 03 9496 5000
Make a difference
Donate
  • Patients & family
    • Becoming our patient
      • How to become an ONJ patient
      • Planning for your care
    • Diagnosis & Treatment
      • Cancer types
      • A new diagnosis
      • Cancer treatment
      • Your Wellness matters
      • Commonly asked questions
    • Clinical Haematology
      • Allogeneic stem cell transplant
      • Autologous stem cell transplant
    • Visitors
  • For health professionals
    • What we do
      • Cancer types & treatment
    • Referral
      • Referral for treatment
      • Referral to palliative care
    • Careers at Austin Health
  • Research
  • About
    • Maps & directions
    • A public hospital with a difference
    • Dame Olivia Newton-John
    • Contact us
  • Ways to help
    • Ways to help today
      • Leave a gift in your Will
      • USA Donations
      • Become a hero today
    • Get Involved
      • Attend an event
      • Corporate partnerships
      • Dry July
    • How your gift helps
      • Why I give
      • People you've helped
      • Impact Report
    • We'll be here for you...but we need your help
Dinesh

Dr Dinesh Raghu

Postdoctoral research fellow

More about Dr Dinesh Raghu

My passion for science began at an early age during my high school studies. I have since then been inspired to dedicate my career to answering critical medical research questions and translating those solutions from a research setting to the clinic.

Having spent the last three-and-a-half years as a PhD student at the Peter MacCallum Cancer Centre, Melbourne, I joined the ONJCRI in 2018 to pursue my research career in cancer immunology. I am currently placed in the Mucosal Immunity and Cancer lab, which is headed by Dr Lisa Mielke. We study how innate immune cells contribute to immunity, inflammatory bowel disease and bowel cancer. We use patient samples, pre-clinical models, and high throughput techniques such as flow cytometry, global- and single-cell RNA sequencing, and multiplex immunofluorescence.

Our ultimate objectives are to target immune cells in inflammatory bowel disease and bowel cancer, to develop better treatments for these diseases, and to establish a platform that can identify patients who will achieve a better clinical outcome from treatments targeting their immune cells to either reduce intestinal damage in inflammatory bowel disease or enhance tumour cell killing in the context of cancer.

I am also actively involved in contributing to school programs by presenting my research work to young inquisitive minds and inspiring them to pursue careers in health science and technology.

Education 

2018 Doctor of Philosophy, The University of Melbourne, Australia

2014 Master of Science by Research, Indian Institute of Technology, India

2011 Bachelor of Technology, Anna University, India

Current Appointments

Postdoctoral Research Fellow, Olivia Newton-John Cancer Research Institute, Melbourne

Honorary Associate, School of Cancer Medicine, La Trobe University

Achievements

2014 - 2018 Melbourne International Fee Remission scholarship (MIFRS), The University of Melbourne

2014 - 2018 Melbourne International Research scholarship (MIRS), The University of Melbourne

2012 – 2014 Ministry of Human Resource and Development Fellowship, Indian Institute of Technology, Madras

2011 Best All Rounder Student award in Undergraduate

2010 Summer Research Fellowship, Indian Academy of Sciences

Recent Publications

  1. Gulati, T., Huang, C., Caramia, F., Raghu, D., Paul, J.P., Goode, R. J.A., Keam, S.P., Williams, S.G., Haupt, S., Kleifeld, O., Schittenhelm, R.B., Gamell, C., Haupt, Y. (2018) Proteomtranscriptomic measurements of E6-Associated Protein (E6AP) targets in DU145 prostate cancer cells. Molecular & Cellular Proteomics.
  2. Raghu, D., Paul, J.P., Gulati, T., Deb, S., Khoo, C., Russo, A., Gallo, E., Blandino, G., Chan, A., Takano, E.A., Fox, S.B., Williams, S., Haupt, S., Gamell, C., Haupt, Y. (2017) E6AP promotes prostate cancer by reducing p27 expression. Oncotarget 8: 42939-48.
  3. Miranda, PJ., Buckley, D., Raghu, D., Pang, J.B., Takano, E.A., Vijayakumaran, R., Teunisse, A., Posner, A., Procter, T., Herold, M.J., Gamell, C., Marine, J.C., Fox, S.B., Jochemsen, A., Haupt, S., Haupt, Y. (2017) MDM4 is a rational target for treating breast cancer with mutant p53. Journal of Pathology 241: 661-70.
  4. Raghu, D*., Piotr, J.P*., Chan, A., Gulati, T., Herold, M.J., Hagekyriakou, J., Vessella, R.l., Fedele, C., Shackleton, M., Williams, E.D., Fox, S.B., Williams, S., Haupt, S., Gamell, C., Haupt, Y. (2016) Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.Oncogene. 35: 6235-645. (*Equal contribution)
  5. Raghu, D and Karunagaran, D. (2014) Plumbagin downregulates WNT signaling independent of p53 in human colorectal cancer cells. Journal of Natural Products. 77: 1130−34.

 

Email: dinesh.raghu@onjcri.org.au

  • Home
  • Ways to help
  • Patients & family
  • For health professionals
  • Research
  • News
  • About
  • ONJ-events
  • Research
  • Collection notice
AustinHealth_Logo
 
Connect with us

Keep up to date with what’s happening at the ONJ Centre.

   

Call us

03 9496 5000

Calling from overseas

+613 9496 5000

Address

145 Studley Road (On the corner of Studley Rd and Bell St) Heidelberg, Victoria, Australia.